$5.76
0.36% day before yesterday
Nasdaq, Apr 25, 10:01 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$5.76
-0.08 1.37% 1M
-0.21 3.52% 6M
+0.12 2.13% YTD
-0.46 7.40% 1Y
-11.17 65.98% 3Y
-26.16 81.95% 5Y
-26.16 81.95% 10Y
Nasdaq, Closing price Fri, Apr 25 2025
-0.02 0.35%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Market capitalization $511.46m
Enterprise Value $57.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.77
P/S ratio (TTM) P/S ratio 15.82
P/B ratio (TTM) P/B ratio 1.04
Revenue growth (TTM) Revenue growth 174.98%
Revenue (TTM) Revenue $32.33m
EBIT (operating result TTM) EBIT $-228.66m
Free Cash Flow (TTM) Free Cash Flow $-161.43m
Cash position $524.28m
EPS (TTM) EPS $-2.35
P/E forward negative
P/S forward 21.15
EV/Sales forward 2.36
Short interest 22.16%
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
32 32
175% 175%
100%
- Direct Costs 6.75 6.75
36% 36%
21%
26 26
1,930% 1,930%
79%
- Selling and Administrative Expenses 45 45
55% 55%
139%
- Research and Development Expense 203 203
10% 10%
627%
-222 -222
4% 4%
-686%
- Depreciation and Amortization 6.75 6.75
36% 36%
21%
EBIT (Operating Income) EBIT -229 -229
2% 2%
-707%
Net Profit -199 -199
1% 1%
-615%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Positive
The Motley Fool
9 days ago
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence.
Positive
Seeking Alpha
11 days ago
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Positive
The Motley Fool
12 days ago
Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 274
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today